District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Washington, District of Columbia
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects
NCT06036199
Recruiting
The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
Gender:
All
Ages:
Between 8 years and 22 years
Trial Updated:
02/08/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Cerebral Palsy, Dyskinetic, Secondary Dystonia
Register for Updates
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
NCT05057702
Recruiting
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with medulloblastoma to receive the most effective and least toxic therapies current... Read More
Gender:
All
Ages:
Between 12 months and 39 years
Trial Updated:
02/08/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Register for Updates
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
NCT04293185
Recruiting
This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using bb1111 (also known as LentiGlobin BB305 Drug Product for SCD).
Gender:
All
Ages:
Between 2 years and 50 years
Trial Updated:
02/07/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease
Register for Updates
MuSK Myasthenia 1000 Study
NCT06259071
Recruiting
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG. The data collected may be used by researchers to gain a better understanding of the cause of MuSK MG and to identify biomarkers and targeted therapy for MuSK MG.
Gender:
All
Ages:
Between 7 years and 99 years
Trial Updated:
02/06/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
Register for Updates
Therapeutic Endpoint in Pediatric IBD Conditions
NCT06065228
Recruiting
The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.
Gender:
All
Ages:
Between 6 years and 21 years
Trial Updated:
02/06/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Systemic Biomarkers of Brain Injury From Hyperammonemia
NCT04602325
Recruiting
Ammonia is a waste product of protein and amino acid catabolism and is also a potent neurotoxin. High blood ammonia levels on the brain can manifest as cytotoxic brain edema and vascular compromise leading to intellectual and developmental disabilities. The following aims are proposed: Aim 1 of this study will be to determine the chronology of biomarkers of brain injury in response to a hyperammonemic (HA) brain insult in patients with an inherited hyperammonemic disorder. Aim 2 will be to det... Read More
Gender:
All
Ages:
Between 7 years and 18 years
Trial Updated:
02/06/2024
Locations: Children's National Research Institute, Washington, District of Columbia
Conditions: Urea Cycle Disorder, Organic Acidemia, Maple Syrup Urine Disease, Glutaric Acidemia I, Fatty Acid Oxidation Disorder, Hypoxic-Ischemic Encephalopathy
Register for Updates
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Register for Updates
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
NCT04171492
Recruiting
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/06/2024
Locations: MedStar, Washington, District of Columbia
Conditions: Nodule Solitary Pulmonary, Non-small Cell Carcinoma
Register for Updates
Orphan Europe Carbaglu® Surveillance Protocol
NCT03409003
Recruiting
The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United States Food and Drug Administration (FDA) for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Much of the FDA-required data is already collected through the Longitudinal Study of Urea Cycle Disorders (RDCRN Protocol #5101). This study will collect additional data on advers... Read More
Gender:
All
Ages:
All
Trial Updated:
02/06/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: N-acetylglutamate Synthase (NAGS) Deficiency
Register for Updates
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
NCT01297400
Recruiting
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Burns
Register for Updates